|
96
|
323
|
4lqmA |
Egfr l858r in complex with pd168393 |
|
68
|
284
|
4mhaA |
Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in complex with inhibitor unc1817 |
|
82
|
272
|
4ll5A |
Crystal structure of pim-1 in complex with the fluorescent compound skf86002 |
|
159
|
464
|
4m84A |
Calcium-dependent protein kinase 1 from toxoplasma gondii (tgcdpk1) in complex with inhibitor uw1455 |
|
81
|
286
|
4m7iA |
Crystal structure of gsk6157 bound to perk (r587-r1092, delete a660-t867) at 2.34a resolution |
|
84
|
263
|
4m15A |
Crystal structure of itk in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1h-pyrazole-3-carboxamide] and adp |
|
97
|
337
|
4mygA |
Mapk13, active form |
|
88
|
263
|
4m14A |
Crystal structure of itk in complex with compound 9 [4-(carbamoylamino)-1-[7-(propan-2-yloxy)naphthalen-1-yl]-1h-pyrazole-3-carboxamide] |
|
88
|
278
|
4mwiA |
Crystal structure of the human mlkl pseudokinase domain |
|
122
|
435
|
4lv7A |
Crystal structure of inositol 1,3,4,5,6-pentakisphosphate 2-kinase e82c/s142c |
|
91
|
317
|
4mneA |
Crystal structure of the braf:mek1 complex |
|
47
|
162
|
4lrkA |
Bacterial effector nleh2 kinase domain |
|
81
|
265
|
4mf1A |
Itk kinase domain in complex with benzothiazole inhibitor 12b (1s,2s)-2-{4-[(dimethylamino)methyl]phenyl}-n-[6-(1h-pyrazol-4-yl)-1,3-benzothiazol-2-yl]cyclopropanecarboxamide |
|
71
|
321
|
4ll0A |
Egfr l858r/t790m in complex with pd168393 |
|
77
|
273
|
4medA |
Crystal structure of ser/thr kinase pim1 in complex with thioridazine derivatives |
|
80
|
274
|
4mbiA |
Discovery of pyrazolo[1,5a]pyrimidine-based pim1 inhibitors |
|
85
|
278
|
4m67A |
Crystal structure of the human mlkl kinase-like domain |
|
84
|
264
|
4m12A |
Crystal structure of itk in complex with compound 7 [4-(carbamoylamino)-1-(7-ethoxynaphthalen-1-yl)-1h-pyrazole-3-carboxamide] |
|
82
|
273
|
4mtaA |
Crystal structure of pim-1 kinase domain in complex with 2-methyl-5-phenylfuran-3-carboxylic acid |
|
77
|
298
|
4lynA |
Crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3-oxazol-2-yl)methyl)sulfanyl)-1,3-thiazol-2-yl)-2-phenylpropanamide |
|
77
|
272
|
4mnfA |
Crystal structure of braf-v600e bound to gdc0879 |
|
72
|
307
|
4lrmA |
Egfr d770_n771insnpg in complex with pd168393 |
|
68
|
285
|
4mh7A |
Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in complex with inhibitor unc1896 |
|
108
|
352
|
4loqA |
Structural basis of autoactivation of p38 alpha induced by tab1 (tetragonal crystal form with bound sulphate) |
|
91
|
329
|
4md9E |
Crystal structure of symmetric ck2 holoenzyme with mutated alpha subunit (f121e truncated at aa 336) |
|
77
|
271
|
4lm5A |
Crystal structure of pim1 in complex with 2-{4-[(3-aminopropyl)amino]quinazolin-2-yl}phenol (resulting from displacement of skf86002) |
|
74
|
278
|
4mcvA |
Star 12 bound to analog-sensitive src kinase |
|
76
|
274
|
4mblA |
Discovery of pyrazolo[1,5a]pyrimidine-based pim1 inhibitors |
|
62
|
284
|
4m3qA |
Crystal structure of the catalytic domain of the proto-oncogene tyrosine-protein kinase mer in complex with inhibitor unc1917 |
|
75
|
277
|
4mxxA |
Human src a403t mutant bound to kinase inhibitor bosutinib |
|
92
|
263
|
4m0yA |
Crystal structure of itk in complex with compound 1 [4-(carbamoylamino)-1-(naphthalen-1-yl)-1h-pyrazole-3-carboxamide] |
|
122
|
346
|
4mq1A |
The crystal structure of dyrk1a with a bound pyrido[2,3-d]pyrimidine inhibitor |
|
106
|
447
|
4ludA |
Crystal structure of hck in complex with the fluorescent compound skf86002 |
|
77
|
274
|
4mneB |
Crystal structure of the braf:mek1 complex |
|
111
|
349
|
4looA |
Structural basis of autoactivation of p38 alpha induced by tab1 (monoclinic crystal form) |
|
110
|
332
|
4md7E |
Crystal structure of full-length symmetric ck2 holoenzyme |
|
80
|
269
|
4lmuA |
Crystal structure of pim1 in complex with the inhibitor quercetin (resulting from displacement of skf86002) |
|
62
|
276
|
4mbjA |
Human b-raf kinase domain in complex with an imidazopyridine-based inhibitor |
|
81
|
303
|
4m8tA |
Rsk2 t493m c-terminal kinase domain in complex with 3-(3-(1h-pyrazol-4-yl)phenyl)-2-cyanoacrylamide |
|
79
|
277
|
4m69B |
Crystal structure of the mouse rip3-mlkl complex |
|
76
|
266
|
4l7sA |
Kinase domain mutant of human itk in complex with an aminobenzothiazole inhibitor |
|
81
|
275
|
4kabA |
Focal adhesion kinase catalytic domain in complex with 3-methyl-1,4-dihydro-pyrazolo[4,5-c]pyrazole |
|
94
|
286
|
4l01A |
Crystal structure of the v658f apo jak1 pseudokinase domain |
|
83
|
270
|
4k8aA |
Fragment-based discovery of focal adhesion kinase inhibitors |
|
101
|
329
|
4kwpA |
Crystal structure of human ck2-alpha in complex with a benzimidazole inhibitor (k164) at 1.25 a resolution |
|
87
|
348
|
4kipA |
Crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with 2-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2-methylphenyl)-1,3-thiazole-5-carboxamide |
|
95
|
291
|
4kbkA |
Ck1d in complex with (3s)-3-{4-[3-(4-fluorophenyl)-1-methyl-1h-pyrazol-4-yl]pyridin-2-yl}morpholine inhibitor |
|
111
|
348
|
4l8mA |
Human p38 map kinase in complex with a dibenzoxepinone |
|
88
|
271
|
4k9yA |
Focal adhesion kinase catalytic domain in complex with 1-[4-(6-amino-purin-9-yl)-phenyl]-3-(5-tert-butyl-2-p-tolyl-2h-pyrazol-3-yl)-urea |
|
105
|
356
|
4kkgA |
Crystal structure of apo and amp-bound jnk3 |
